Table 1 Patient characteristics (n = 134)
Age | Median (years) | 53 |
|  | Range | 10–78 |
Bone tumor | Â | 29 (21.6%) |
 Primary site | Humerus | 2 (1.5%) |
| Â | Spine | 6 (4.5%) |
| Â | Femur | 16 (11.9%) |
| Â | Tibia | 3 (2.2%) |
| Â | Others | 2 (1.5%) |
Soft tissue tumor | Â | 105 (78.4%) |
 Primary site | Head and neck | 4 (3.0%) |
| Â | Shoulder girdle | 3 (2.2%) |
| Â | Upper arm | 3 (2.2%) |
| Â | Forearm | 6 (4.5%) |
| Â | Other upper extremity | 5 (3.7%) |
| Â | Chest wall | 4 (3.0%) |
| Â | Buttock | 6 (4.5%) |
| Â | Retroperitoneum | 14 (10.4%) |
| Â | Visceral | 10 (7.5%) |
| Â | Thigh | 25 (18.7%) |
| Â | Leg | 9 (6.7%) |
| Â | Other lower extremity | 9 (6.7%) |
| Â | Others | 7 (5.2%) |
Histological subtype | ||
| Â | Leiomyosarcoma | 38 (28.4%) |
| Â | Undifferentiated pleomorphic sarcoma | 20 (14.9%) |
| Â | Osteosarcoma | 17 (12.7%) |
| Â | Liposarcoma | 9 (6.7%) |
| Â | Synovial sarcoma | 7 (5.2%) |
| Â | Malignant peripheral nerve sheath tumor | 7 (5.2%) |
| Â | Angiosarcoma | 4 (3.0%) |
| Â | Ewing sarcoma | 4 (3.0%) |
| Â | Epithelioid sarcoma | 4 (3.0%) |
| Â | Rhabdomyosarcoma | 3 (2.2%) |
| Â | Others | 21 (15.7%) |
Presentation status | ||
| Â | Localized | 9 (6.7%) |
| Â | Metastatic or locally advanced | 125 (93.3%) |
Prior chemotherapy regimen | ||
| Â | DOX+IFO | 38 (28.4%) |
| Â | DOX alone | 21 (15.7%) |
| Â | IFO alone | 18 (13.4%) |
| Â | IFO+VP16 | 12 (9.0%) |
| Â | IFO+CDBCA+VP16 | 11 (8.2%) |
| Â | DOX+CDDP | 6 (4.5%) |
| Â | None | 32 (23.9%) |
Prior radiation | Â | 45 (33.6%) |